Other Event

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Other Event

Other Adverse Events are non-serious adverse events that exceed a specific frequency threshold (typically 5% within any study arm). These events are reported to provide comprehensive safety information about all noteworthy adverse occurrences during clinical trials. Each other event is categorized by term, organ system, assessment type, and source vocabulary for standardized reporting.

Other Event path is as follows:

Study -> Results Section -> Adverse Events Module -> Other Event

Study -> Results Section -> Adverse Events Module -> Other Event -> Other Event Stats

Other Event

Ignite Creation Date: 2025-12-24 @ 11:15 PM
Ignite Modification Date: 2025-12-25 @ 8:52 PM
NCT ID: NCT03580356
Term: Dermatitis contact
Organ System: Skin and subcutaneous tissue disorders
Assessment Type: SYSTEMATIC_ASSESSMENT
Source Vocabulary: MedDRA (25.0)
Notes: None
Study: NCT03580356
Study Brief: A Phase III Study of and Efficacy of Ligelizumab in the Treatment of CSU in Adolescents and Adults Inadequately Controlled With H1-antihistamines.
Other Event Stats (If Any):

Other Event Stats

Group ID # Events # Affected # At Risk View
EG000 None 5 304 View
EG001 None 0 16 View
EG002 None 5 320 View
EG003 None 9 306 View
EG004 None 0 19 View
EG005 None 9 325 View
EG006 None 3 307 View
EG007 None 0 14 View
EG008 None 3 321 View
EG009 None 0 103 View
EG010 None 0 6 View
EG011 None 0 109 View
EG012 None 1 90 View
EG013 None 0 6 View
EG014 None 1 96 View